• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017

Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017

November 3, 2017 By Fink Densford

Hologic CEO MacMillan

Hologic (NSDQ:HOLX) said this week its current prez and CEO Stephen MacMillan will stay on with the company, resolving rumors that he may depart it to take up the corner office at Zimmer Biomet (NYSE:ZBH).

In an SEC filing, the Marlborough, Mass.-based company’s board said it approved a special “performance-based retention equity grant” to MacMillan after he had begun to receive interest from other medical device firms.

“Mr. MacMillan has led a dramatic turnaround of Hologic since joining in December 2013. The company’s performance has increased significantly under his leadership and he personally has recruited a large number of leaders to the company. In light of his long track record of success, other larger medical device companies have expressed interest over time in retaining him to serve as chief executive officer. Mr. MacMillan recently received such an offer from a large medical device company. The independent members of the company’s board of directors considered the potential for disruption to Hologic and its business should Mr. MacMillan leave, and determined that it was in the best interests of Hologic and its stockholders to retain him as chairman, president and chief executive officer. Accordingly, the independent members of the board, after careful consideration and discussions with Mr. MacMillan and the compensation committee’s compensation consultant, awarded him a special retention equity grant, all of which is performance-based. He has formally declined the other more substantial offer, reaffirmed his full commitment to Hologic, and will remain as chairman, president and chief executive officer of Hologic,” the company wrote in an SEC filing.

The news could be a boon for the company, according to a Leerink Partner analyst’s report, as the possibility of his departure “has been an overhang on the stock.”

“The board believed (appropriately in our view) it was in the best interest of HOLX shareholders after considering the disruption to HOLX and the business should he leave to issue a retention package which amounts to a combined ~$20M of equity grants (50% tied to return on invested capital metrics and 50% tied to total shareholder return metrics), and $10M in the form of options that vest in 4 equal installments over four years,” Leerink Partner analyst Richard Newitter wrote in a letter to investors.

Shares in Hologic are up 3.2% today, at $39.65 as of 11:43 a.m. EDT.

 

 Tissue Regenix taps ex-Global Sanofi Biosurgery COO Caldwell as chief exec

Tissue Regenix (LON:TRX) has reportedly tapped Steve Caldwell as its chief executive officer, effective immediately.

The promotion lifts Couldwell from his place as a non-executive director, which he’s held since July 2013. Prior to joining Tissue Regenix, Caldwell held a number of positions with Smith & Nephew (NYSE:SNN) including European orthopedics prez and sales and marketing senior VP.

Most recently, he held a position as chief operating officer for Global Sanofi Biosurgery.

“Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7B US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world,” Caldwell said, according to a Hargreaves Lansdown report.

Read more

 ConMed CFO Pomilio to retire

ConMed (NSDQ:CNMD) said this week its CFO Luke Pomilio will retire from his position with the company, but will remain on until a successor is found.

The Utica, N.Y.-based company said it has already initiated a search for a new CFO. Pomilio has served as CFO at the company since April, 2015 and originally joined as a Controller in 1995.

“On behalf of the board and the entire ConMed team, I would like to thank Luke for his invaluable contributions to the improvement of the company’s commercial execution, to the development of our financial organization, and to ConMed as a whole. We appreciate his commitment to our company and its shareholders during his distinguished career here, and we wish him the very best as he transitions into retirement,” prez & CEO Curt Hartman said in a prepared statement.

“I have been honored to be a part of the ConMed team for the last two decades and to lead its finance team for the past several years. I am proud of the progress we have made in strengthening the Company’s profile, and I am confident that ConMed is well positioned for growth and success,” Pomilio said in a press release.

Read more

 Invacare CFO Gudbranson to step away

Invacare (NYSE:IVC) said this week its chief financial officer Robert Gudbranson will step away from the company to pursue other opportunities, effective November 26.

The Elyria, Ohio-based company said it is engaging in an executive search for a successor, with corporate controller and VP Kathleen Leneghan assuming the CFO role on an interim basis.

“On behalf of everyone at Invacare and our Board of Directors, I want to thank Rob for his financial leadership and many contributions during his tenure as CFO, including serving as interim CEO from July 2014 to March 2015. We wish him success in his new endeavor. We have full confidence in Kathy’s ability to lead our finance operations, and we expect a smooth transition. We are grateful for her experience and leadership while our search is underway for a new chief financial officer. Based on our progress with our business transformation, this is a good transition point. We look forward to updating investors on our third quarter financial results in next week’s earnings call,” prez & CEO Matthew Monaghan said in a press release.

“I have enjoyed working at Invacare, and I wish the company well. I remain fully committed to helping Matt, Kathy and the Invacare team ensure a seamless transition over the next several weeks,” Gudbranson said in a prepared statement.

Read more

 Pulmatrix taps former Veristat exec as chief med officer

Pulmatrix (NSDQ:PULM) said late last month it tapped former Veristat chief medical officer Dr. Jim Roach as its new chief medical officer, effective today.

In his position, Dr. Roach will head the clinical development of the company’s inhaled drugs for serious lung diseases including allergic bronchopulmonary aspergillosis and chronic obstructive lung disease, the Lexington, Mass.-based company said.

“We are excited to have Dr. Roach join the Pulmatrix team to oversee and accelerate the clinical development of our pipeline. Dr. Roach is an ideal person for the job, as a board-certified pulmonologist with many years of experience in successfully managing clinical development and operations, as well as medical and regulatory affairs, in a number of biotech and pharma companies,” CEO Robert Clarke said in a press release.

“I am very excited to be joining Pulmatrix at a time when its lead compounds emerging from the iSperse platform are so close to entering the clinic I look forward to working with the team to advance these innovative therapies that hopefully can make a meaningful difference in the lives of patients suffering from these chronic illnesses,” Dr. Roach said in a prepared statement.

Read more

  • Lonford Capital adds patent Atty. Ahn
  • Kent Imaging hires Hydar as sales VP
  • Meritech adds to exec roster

Filed Under: Business/Financial News Tagged With: ConMed Corp., Hologic, Invacare, kentimaging, Meritech Capital Partners, Pulmatrix Inc., Sanofi-Aventis, Smith & Nephew, Tissue Regenix, Zimmer Biomet

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS